D. Aubert

3.3k total citations · 1 hit paper
31 papers, 2.2k citations indexed

About

D. Aubert is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, D. Aubert has authored 31 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 5 papers in Surgery. Recurrent topics in D. Aubert's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (11 papers) and Lung Cancer Research Studies (11 papers). D. Aubert is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Treatment and Pharmacology (11 papers) and Lung Cancer Research Studies (11 papers). D. Aubert collaborates with scholars based in France, Spain and Germany. D. Aubert's co-authors include Stephen Spiro, Rafael Rosell, Jean‐Pierre Pignon, Lesley Seymour, Keyue Ding, Thierry Le Chevalier, Hélène Tribodet, Jean-Yves Douillard, Frances A. Shepherd and Richard Stephens and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

D. Aubert

30 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

2008 1.8k citations Jean‐Pierre Pignon, Hélène Tribodet et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
D. Aubert France	11	1.8k	1.2k	287	279	254	31	2.2k
Pasquale Comella Italy	17	780 0.4×	1.2k 1.0×	175 0.6×	150 0.5×	249 1.0×	55	1.6k
Jayaprakash Madhavan India	19	1.1k 0.6×	863 0.7×	243 0.8×	197 0.7×	456 1.8×	40	1.9k
Zhouguang Hui China	22	1.1k 0.6×	575 0.5×	378 1.3×	217 0.8×	256 1.0×	145	1.7k
Maria Q. Baggstrom United States	17	922 0.5×	743 0.6×	152 0.5×	300 1.1×	406 1.6×	65	1.5k
C. Manegold Germany	17	1.0k 0.6×	1.1k 1.0×	104 0.4×	127 0.5×	390 1.5×	58	1.6k
Motohiro Tamiya Japan	23	1.3k 0.7×	1.2k 1.0×	112 0.4×	189 0.7×	317 1.2×	163	1.9k
Yasuhiro Tsutani Japan	31	2.7k 1.5×	765 0.6×	933 3.3×	293 1.1×	381 1.5×	178	3.3k
V. Georgoulias Greece	18	386 0.2×	731 0.6×	413 1.4×	242 0.9×	263 1.0×	51	1.4k
Miloš Pešek Czechia	21	1.7k 1.0×	1.6k 1.4×	74 0.3×	408 1.5×	650 2.6×	110	2.4k
Saulius Cicėnas Lithuania	12	1.4k 0.7×	1.1k 0.9×	57 0.2×	230 0.8×	320 1.3×	45	1.7k

Countries citing papers authored by D. Aubert

Since Specialization

Citations

This map shows the geographic impact of D. Aubert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Aubert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Aubert more than expected).

Fields of papers citing papers by D. Aubert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Aubert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Aubert. The network helps show where D. Aubert may publish in the future.

Co-authorship network of co-authors of D. Aubert

This figure shows the co-authorship network connecting the top 25 collaborators of D. Aubert. A scholar is included among the top collaborators of D. Aubert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Aubert. D. Aubert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Douillard, Jean-Yves, Hélène Tribodet, D. Aubert, et al.. (2010). Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation. Journal of Thoracic Oncology. 5(2). 220–228. 183 indexed citations

Millet, Guillaume Y., D. Aubert, F. Favier, Thierry Busso, & H. Benoît. (2009). Effect of acute hypoxia on central fatigue during repeated isometric leg contractions. Scandinavian Journal of Medicine and Science in Sports. 19(5). 695–702. 28 indexed citations

Gottfried, Maya, Rodryg Ramlau, Maciej Krzakowski, et al.. (2008). Cisplatin-Based Three Drugs Combination (NIP) as Induction and Adjuvant Treatment in Locally Advanced Non-small Cell Lung Cancer: Final Results. Journal of Thoracic Oncology. 3(2). 152–157. 23 indexed citations

Pignon, Jean‐Pierre, Hélène Tribodet, Giorgio V. Scagliotti, et al.. (2008). Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. Journal of Clinical Oncology. 26(21). 3552–3559. 1752 indexed citations breakdown →

Tubiana-Mathieu, N., Philippe Bougnoux, D. Becquart, et al.. (2007). An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology. 25(18_suppl). 1056–1056. 2 indexed citations

Beckmann, Gabriele, Rainer Fietkau, Rudolf M. Huber, et al.. (2006). Oral Vinorelbine and Cisplatin with Concomitant Radiotherapy in Stage III Non-Small Cell Lung Cancer (NSCLC): A Feasibility Study. Oncology Research and Treatment. 29(4). 137–142. 15 indexed citations

Chan, Arlene, Michael Untch, Marta Gil, et al.. (2006). Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer. 95(7). 788–793. 37 indexed citations

Chan, Arlene, N. Tubiana-Mathieu, Vinod Ganju, et al.. (2006). Optimal tolerance of an all-oral combination chemotherapy (CT) of oral vinorelbine (NVBo), capecitabine (C) with/without trastuzumab (T) in metastatic breast cancer (MBC) patients (pts): Safety Results of two international multicenter studies. Journal of Clinical Oncology. 24(18_suppl). 10607–10607. 3 indexed citations

Rosell, R., M. De Lena, Francesco Carpagnano, et al.. (2005). Pr3 ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I–III) non small cell lung cancer (NSCLC) patients (pts). Lung Cancer. 49. S3–S4. 11 indexed citations

10.

Chan, Anthony T.�C., Luboš Petruželka, Michael Untch, et al.. (2005). Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts). Journal of Clinical Oncology. 23(16_suppl). 587–587. 8 indexed citations

11.

Gridelli, Cesare, C. Manegold, P Mali, et al.. (2004). Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. European Journal of Cancer. 40(16). 2424–2431. 36 indexed citations

12.

Grunenwald, Dominique, Jubrail Dahabreh, Francesco Carpagnano, et al.. (2004). The triplet vinorelbine (NVB), ifosfamide (IFO) and cisplatin (CDDP) (NIP) used as post-operative treatment versus surgery alone in patients having received primary chemotherapy (CT) for locally advanced (LA) non small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7172–7172. 1 indexed citations

13.

Mali, P, Filippo de Marinis, C. Manegold, et al.. (2004). Single agent oral vinorelbine (NVB) in advanced non-small cell lung cancer (NSCLC) in the elderly: Patient benefit improvement by weekly schedule. Journal of Clinical Oncology. 22(14_suppl). 7120–7120. 3 indexed citations

14.

Aubert, D., et al.. (2004). [Bladder augmentation cystoplasty with continent urinary diversion by ileo-caeco-appendicular graft in children].. PubMed. 14(4). 525–9. 1 indexed citations

15.

Souquet, P.-J., et al.. (2003). GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patientsAnn Oncol 2002; 13: 1853–1861. Annals of Oncology. 14(2). 347–347. 1 indexed citations

16.

Jassem, Jacek, P. Kosmidis, Rodryg Ramlau, et al.. (2003). Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Annals of Oncology. 14(11). 1634–1639. 34 indexed citations

17.

Gridelli, Cesare, Filippo de Marinis, Christian Manegold, et al.. (2003). O-144 Result of a phase II study conducted in elderly patients with unresectable localised or metastatic non-small-cell-lung cancer (NSCLC) with oral vinorelbine given as a weekly monotherapy. Lung Cancer. 41. S44–S44. 2 indexed citations

18.

Chen, Yuh‐Min, James Chih‐Hsin Yang, Chong‐Jen Yu, et al.. (2003). P-544 Final results of a phase I study with navelbine (NVB) oral in combination with cisplatin (C), evaluating two different schedules in advanced non-small cell lung cancer (NSCLC) patients. Lung Cancer. 41. S229–S229. 1 indexed citations

19.

Souquet, P.-J., E.H. Tan, José Rodrigues Pereira, et al.. (2002). GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine–cisplatin with vinorelbine–ifosfamide–cisplatin in metastatic non-small-cell lung cancer patients. Annals of Oncology. 13(12). 1853–1861. 50 indexed citations

20.

Pignon, B., et al.. (1990). Evaluation of the efficacy of prophylactic intravenous antibiotherapy with ceftriaxone in post-chemotherapy agranulocytic patients.. PubMed. 32(4). 249–52. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact